{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DART&page=2", "query": { "intervention": "DART", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DART&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-04T07:57:09.552Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02152956", "title": "Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "AML" ], "interventions": [ { "name": "Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 30 ng/kg/day, 4 days on and 3 days off", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 100 ng/kg/day, 4 days on and 3 days off", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in dose", "type": "BIOLOGICAL" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in dose", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 244, "start_date": "2014-06-09", "completion_date": "2022-07-05", "has_results": true, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-09-04T07:57:09.552Z", "location_count": 20, "location_summary": "Duarte, California • La Jolla, California • San Francisco, California + 16 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02152956" }, { "nct_id": "NCT04568356", "title": "A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "SARS CoV-2" ], "interventions": [ { "name": "Direct Antigen Tests for COVID-19", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "E25Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2020-04-24", "completion_date": "2020-09-24", "has_results": false, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-09-04T07:57:09.552Z", "location_count": 3, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04568356" }, { "nct_id": "NCT02248805", "title": "Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Carcinoma" ], "interventions": [ { "name": "MGD007", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2014-10", "completion_date": "2018-07-02", "has_results": false, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-09-04T07:57:09.552Z", "location_count": 8, "location_summary": "New Haven, Connecticut • Tampa, Florida • Baltimore, Maryland + 4 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02248805" }, { "nct_id": "NCT06730347", "title": "A Study of Lorigerlimab in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Platinum-resistant Ovarian Cancer", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Clear Cell Adenocarcinoma of Ovary", "Clear Cell Adenocarcinoma of Vulva", "Clear Cell Adenocarcinoma of Vagina", "Clear Cell Adenocarcinoma of Cervix", "Clear Cell Adenocarcinoma of Uterus", "Clear Cell Adenocarcinoma of Fallopian Tube", "Clear Cell Adenocarcinoma of Peritoneum", "Endometrial Cancer" ], "interventions": [ { "name": "Lorigerlimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 80, "start_date": "2025-05-01", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-06-02", "last_synced_at": "2026-09-04T07:57:09.552Z", "location_count": 7, "location_summary": "Los Angeles, California • New Orleans, Louisiana • Grand Rapids, Michigan + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06730347" }, { "nct_id": "NCT02908477", "title": "Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Oropharynx Cancer" ], "interventions": [ { "name": "Adjuvant Radiation Therapy", "type": "RADIATION" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 228, "start_date": "2016-10-03", "completion_date": "2024-11-15", "has_results": true, "last_update_posted_date": "2025-02-11", "last_synced_at": "2026-09-04T07:57:09.552Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02908477" }, { "nct_id": "NCT00116415", "title": "DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections", "AIDS" ], "interventions": [ { "name": "efavirenz; didanosine EC; lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2002-03", "completion_date": "2004-11", "has_results": false, "last_update_posted_date": "2011-04-22", "last_synced_at": "2026-09-04T07:57:09.552Z", "location_count": 9, "location_summary": "Washington D.C., District of Columbia • Orlando, Florida • Columbus, Georgia + 6 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Columbus", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Springfield", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00116415" }, { "nct_id": "NCT02943551", "title": "Dialogue Around Respiratory Illness Treatment", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Respiratory Disease", "Acute Respiratory Infection", "Respiratory Infection", "Upper Respiratory Infection" ], "interventions": [ { "name": "Online Tutorial", "type": "OTHER" }, { "name": "Webinars", "type": "OTHER" }, { "name": "Booster Sessions", "type": "OTHER" }, { "name": "Feedback Reports", "type": "OTHER" }, { "name": "Parent Survey", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Seattle Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "10 Years", "sex": "ALL", "summary": "6 Months to 10 Years" }, "enrollment_count": 2728, "start_date": "2016-07-18", "completion_date": "2020-06-30", "has_results": false, "last_update_posted_date": "2019-07-16", "last_synced_at": "2026-09-04T07:57:09.552Z", "location_count": 20, "location_summary": "Paragould, Arkansas • Eureka, California • Durango, Colorado + 16 more", "locations": [ { "city": "Paragould", "state": "Arkansas" }, { "city": "Eureka", "state": "California" }, { "city": "Durango", "state": "Colorado" }, { "city": "Wallingford", "state": "Connecticut" }, { "city": "Bradenton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02943551" }, { "nct_id": "NCT04681105", "title": "Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Acute Leukemia", "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent Hairy Cell Leukemia", "Recurrent Hematologic Malignancy", "Recurrent Hodgkin Lymphoma", "Recurrent T Acute Lymphoblastic Leukemia", "Refractory Acute Leukemia", "Refractory B Acute Lymphoblastic Leukemia", "Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm", "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Refractory Hairy Cell Leukemia", "Refractory Hematologic Malignancy", "Refractory Hodgkin Lymphoma", "Refractory T Acute Lymphoblastic Leukemia", "Systemic Mastocytosis" ], "interventions": [ { "name": "Acetaminophen", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Diphenhydramine", "type": "DRUG" }, { "name": "Flotetuzumab", "type": "BIOLOGICAL" }, { "name": "Ibuprofen", "type": "DRUG" }, { "name": "Ranitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 13, "start_date": "2020-11-18", "completion_date": "2025-08-05", "has_results": false, "last_update_posted_date": "2026-01-28", "last_synced_at": "2026-09-04T07:57:09.552Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04681105" }, { "nct_id": "NCT00116116", "title": "DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections", "AIDS" ], "interventions": [ { "name": "efavirenz, stavudine extended release, lamivudine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2002-03", "completion_date": "2005-06", "has_results": false, "last_update_posted_date": "2011-04-26", "last_synced_at": "2026-09-04T07:57:09.552Z", "location_count": 10, "location_summary": "Bakersfield, California • San Francisco, California • Washington D.C., District of Columbia + 7 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00116116" }, { "nct_id": "NCT06940297", "title": "Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Ciltacabtagene Autoleucel", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quercetin", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2025-09-18", "completion_date": "2031-08-15", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-04T07:57:09.552Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06940297" } ] }